Loading…
Jenburkt Pharmaceuticals (BSE 524731)₹948.40−0.88%Pharmaceuticals
In the Jun 2026 quarter (standalone), Jenburkt Pharmaceuticals reported sales of ₹35.60 Cr, up 0.0% from Jun 2025, and net profit of ₹5.90 Cr, down 24.4% year on year. For the year to Mar 2026, sales were ₹169 Cr and net profit ₹35.02 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38.40 | 35.75 | 38.93 | 32.61 | 41.37 | 36.97 | 41.15 | 35.60 | 45.67 | 43.12 | 44.73 | 35.60 |
| Expenses | 29.21 | 28.49 | 28.98 | 23.29 | 29.82 | 28.06 | 30.18 | 26.59 | 32.48 | 35.60 | 30.37 | 29.51 |
| Operating Profit | 9.13 | 7.21 | 9.88 | 9.32 | 11.47 | 8.85 | 10.90 | 8.99 | 13.15 | 7.46 | 14.29 | 6.05 |
| OPM % | 23.8% | 20.2% | 25.4% | 28.6% | 27.8% | 24.0% | 26.5% | 25.2% | 28.9% | 17.3% | 32.0% | 17.1% |
| Other Income | 1.11 | 1.36 | 1.20 | 1.42 | 1.86 | 1.59 | 1.89 | 2.07 | 2.09 | 1.83 | 0.41 | 1.52 |
| Interest | 0.08 | 0.08 | 0.07 | 0.12 | 0.13 | 0.12 | 0.12 | 0.12 | 0.12 | 0.13 | 0.14 | 0.14 |
| Depreciation | 0.60 | 0.64 | 0.63 | 0.53 | 0.65 | 0.79 | 0.78 | 0.73 | 0.75 | 0.84 | 0.82 | 0.65 |
| Profit before tax | 9.51 | 7.81 | 10.32 | 10.02 | 12.47 | 9.47 | 11.80 | 10.14 | 14.29 | 8.27 | 13.67 | 6.74 |
| Tax % | 23.2% | 31.1% | 23.9% | 26.3% | 23.3% | 31.6% | 27.9% | 23.5% | 29.1% | 28.5% | 20.8% | 13.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.91 | 0.00 |
| Net Profit | 7.33 | 5.41 | 7.89 | 7.43 | 9.61 | 6.52 | 8.55 | 7.80 | 10.17 | 5.94 | 10.86 | 5.90 |
| EPS (Rs) | 16.64 | 12.27 | 17.89 | 16.85 | 21.78 | 14.79 | 19.40 | 17.68 | 23.08 | 13.47 | 24.62 | 13.39 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94.22 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 | 152 | 169 | 169 |
| Expenses | 77.04 | 83.98 | 91.04 | 98.02 | 98.99 | 88.97 | 96.99 | 106 | 109 | 111 | 125 | 128 |
| Operating Profit | 16.07 | 20.08 | 24.09 | 25.10 | 20.06 | 20.05 | 27.07 | 30.11 | 33.10 | 40.15 | 44.13 | 40.95 |
| OPM % | 18.1% | 19.1% | 21.1% | 20.1% | 17.1% | 18.1% | 22.1% | 22.1% | 23.0% | 27.1% | 26.1% | 24.2% |
| Other Income | 3.01 | 3.01 | 3.01 | 3.01 | 4.01 | 4.01 | 5.02 | 5.02 | 5.01 | 7.02 | 6.02 | 5.85 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 |
| Depreciation | 1.99 | 2.01 | 2.01 | 1.01 | 2.01 | 2.01 | 1.99 | 1.99 | 2.01 | 2.99 | 3.01 | 3.06 |
| Profit before tax | 16.93 | 19.92 | 24.89 | 26.90 | 20.93 | 21.91 | 29.87 | 32.87 | 34.85 | 43.83 | 46.86 | 42.97 |
| Tax % | 36.0% | 34.0% | 32.0% | 26.0% | 30.0% | 24.0% | 25.0% | 25.0% | 26.0% | 27.0% | 25.0% | — |
| Exceptional items | 0.00 | 0.09 | 0.04 | −0.01 | 0.00 | 0.00 | 0.15 | 0.00 | 0.05 | 1.03 | −2.62 | −2.91 |
| Net Profit | 11.01 | 14.01 | 16.99 | 19.99 | 15.01 | 16.02 | 22.02 | 25.01 | 26.02 | 32.04 | 35.02 | 32.87 |
| EPS (Rs) | 23.24 | 29.14 | 37.59 | 43.21 | 32.45 | 36.01 | 48.67 | 55.88 | 58.97 | 72.83 | 78.86 | 74.56 |
| Dividend payout % | 31.1% | 28.0% | 24.1% | 24.1% | 25.1% | 28.1% | 25.0% | 26.0% | 26.0% | 25.1% | 26.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.99 | 4.99 | 4.98 | 4.99 | 4.99 | 4.98 | 4.99 | 4.98 | 3.99 | 3.99 | 3.99 | 3.99 |
| Reserves | 28.98 | 35.97 | 49.97 | 56.95 | 72.97 | 74.94 | 93.98 | 113 | 118 | 141 | 167 | 193 |
| Borrowings | 7.01 | 5.01 | 6.01 | 0.00 | 7.01 | 3.01 | 5.01 | 7.01 | 3.00 | 0.00 | 4.00 | 2.01 |
| Other Liabilities | 20.98 | 11.99 | 15.94 | 15.97 | 17.93 | 20.95 | 16.94 | 17.91 | 15.92 | 18.91 | 18.91 | 25.87 |
| Total Liabilities | 60.96 | 57.96 | 75.90 | 76.91 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
| Fixed Assets | 11.99 | 11.99 | 10.98 | 9.98 | 9.98 | 11.99 | 10.99 | 10.99 | 9.98 | 9.99 | 14.99 | 18.98 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 39.84 | 45.81 |
| Investments | 0.00 | 1.01 | 2.01 | 5.01 | 5.01 | 4.01 | 7.01 | 8.01 | 11.01 | 17.02 | 21.03 | 27.04 |
| Other Assets | 48.97 | 44.96 | 63.91 | 61.92 | 86.92 | 87.88 | 103 | 123 | 119 | 136 | 120 | 132 |
| Inventories | 8.01 | 8.01 | 11.01 | 6.99 | 10.01 | 10.99 | 7.99 | 9.99 | 8.01 | 8.99 | 9.01 | 14.01 |
| Trade receivables | 6.99 | 5.99 | 8.99 | 12.99 | 22.98 | 17.98 | 13.99 | 14.98 | 16.99 | 19.01 | 20.98 | 23.99 |
| Cash & equivalents | 27.99 | 29.99 | 41.96 | 40.99 | 51.99 | 57.99 | 56.99 | 49.02 | 53.94 | 78.98 | 24.99 | 53.02 |
| Total Assets | 60.96 | 57.96 | 75.90 | 76.91 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 8.99 | 7.99 | 9.99 | 15.98 | 12.99 | 14.99 | 18.99 | 8.99 | 16.99 | 7.99 | 28.01 | 26.99 |
| Cash from investing activity | 1.01 | 0.00 | −10.02 | 1.01 | −11.02 | −3.01 | −19.05 | −1.01 | 3.01 | −1.01 | −17.02 | −19.04 |
| Cash from financing activity | 0.99 | −4.99 | 0.99 | −17.99 | −1.99 | −10.99 | −0.99 | −5.99 | −20.99 | −6.99 | −7.99 | −8.99 |
| Net cash flow | 11.01 | 2.01 | 0.99 | −0.99 | 0.00 | 0.99 | 0.00 | 3.01 | −1.01 | 0.00 | 3.01 | −2.01 |
| Capex | 0.80 | 2.54 | 0.38 | 0.46 | 2.41 | 4.56 | 1.16 | 3.06 | 2.11 | 2.56 | 19.73 | 13.74 |
| Free cash flow | 8.02 | 5.01 | 10.03 | 16.03 | 11.02 | 11.03 | 18.03 | 7.02 | 15.04 | 6.01 | 8.02 | 13.02 |
| CFO / OP % | 88.1% | 82.1% | 85.1% | 103.1% | 80.0% | 104.1% | 127.1% | 62.1% | 83.1% | 49.1% | 102.1% | 88.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 32 | 23 | 32 | 40 | 68 | 55 | 47 | 45 | 45 | 50 | 50 | 53 |
| Inventory days | 108 | 110 | 129 | 74 | 100 | 121 | 93 | 116 | 93 | 104 | 110 | 155 |
| Days payable | 53 | 43 | 71 | 43 | 65 | 57 | 55 | 82 | 66 | 74 | 99 | 90 |
| Cash conversion cycle | 85 | 88 | 89 | 69 | 101 | 117 | 83 | 77 | 70 | 78 | 59 | 115 |
| Working capital days | −11 | 6 | 10 | 25 | 35 | 32 | 17 | 16 | 31 | 36 | 31 | 41 |
| ROCE % | 42.0% | 40.0% | 39.0% | 42.0% | 37.0% | 26.0% | 24.0% | 26.0% | 27.0% | 26.0% | 27.0% | 27.0% |
For the Jun 2026 quarter, Jenburkt Pharmaceuticals reported sales of ₹35.60 Cr, up 0.0% year on year and net profit of ₹5.90 Cr, down 24.4% year on year. The operating margin was 17.1%.
Jenburkt Pharmaceuticals' sales for the year to Mar 2026 were ₹169 Cr; over the last twelve months they were ₹169 Cr.
Net profit for the year to Mar 2026 was ₹35.02 Cr, and ₹32.87 Cr over the last twelve months. Earnings per share over the same trailing period were ₹74.56.
Jenburkt Pharmaceuticals reported borrowings of ₹2.01 Cr at Mar 2026, against cash and equivalents of ₹53.02 Cr.
Cash from operations was ₹26.99 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹13.02 Cr.